ProCE Banner Activity

CE / CME

Cases and Challenges in the Optimal Treatment of Advanced Gastric Cancer

Text Module

Get up to date with information and expert insights on caring for patients with advanced gastric cancer with this interactive text module from Steven Maron, MD.

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurse Practitioners: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Released: April 27, 2023

Expiration: April 26, 2024

Share

Faculty

Steven Maron

Steven Maron, MD

Assistant Attending Physician
Gastrointestinal Medical Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Partners for Advancing Clinical Education (PACE)

ProCE Banner

Supporters

Supporter by educational grants from AstraZeneca, Daiichi Sankyo, and Merck Sharp & Dohme Corp.

AstraZeneca

Daiichi Sankyo, Inc.

Target Audience

NPs, PAs, and nurses who specialize in oncology

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify current recommendations for molecular testing in advanced gastric cancer

  • Compose treatment strategies for patients with gastric cancer based on molecular testing, guideline recommendations, clinical trial evidence, and patient and disease factors

  • Use recommended approaches to manage AEs associated with novel therapies

Disclosure

Partners for Advancing Clinical Education (PACE) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Steven Maron, MD

Assistant Attending Physician
Gastrointestinal Medical Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Steven Maron, MD: consultant/advisor/speaker: Amgen, Basilea, Bicara, Daiichi Sankyo, Elevation Oncology, Novartis; researcher: Epic Sciences, Guardant Health; stock/stock options: Calithera.

The planners and content peer reviewers from Partners for Advancing Clinical Education and Practicing Clinicians Exchange do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from April 27, 2023, through April 26, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities

Accreditation

Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

ANCC Credit Designation
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.00 contact hours, including 1.00 hours of pharmacology credit. 

AAPA Credit Designation
Joint AccreditationPartners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until April 26, 2024. PAs should only claim credit commensurate with the extent of their participation. 

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.